Proteasome inhibitor bortezomib for the treatment of multiple myeloma
نویسندگان
چکیده
منابع مشابه
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Multiple myeloma (MM), a malignancy of the plasma cells, accounts for an estimated 14% of all newly diagnosed hematologic malignancies. Advances in chemotherapy and stem cell transplantation have improved survival rates, but MM remains incurable. Bortezomib (Velcade, Millennium Pharmaceuticals, Inc., Cambridge, MA), a first-in-class proteasome inhibitor, has been approved for patients with MM w...
متن کاملBortezomib / proteasome inhibitor PS - 341 resistance in multiple myeloma
198 words; Text4628 words Blood First Edition Paper, prepublished online June 24, 2004; DOI 10.1182/blood-2004-02-0547 Copyright (c) 2004 American Society of Hematology only. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From
متن کاملBortezomib for the treatment of multiple myeloma.
Bortezomib is the first proteasome inhibitor drug tested in human patients. Bortezomib demonstrates a particular clinical utility in the treatment of multiple myeloma (MM), where it is the only one of the new drugs administered as mono-therapy that prolongs survival. The significant problem for the consistent pursuit of bortezomib was neurotoxicity, which has been significantly reduced by regis...
متن کاملCarfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Although the incidence of multiple myeloma (MM) is increasing, the median overall survival and the number of agents in the pipeline for treating MM also are increasing. Response rates higher than 80% are not uncommon in the frontline setting when the novel agents thalidomide, lenalidomide, and bortezomib are used in combination. Response rates and survival also have improved in disease that has...
متن کاملBortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
BACKGROUND Multiple myeloma (MM) is an incurable malignancy that is diagnosed in approximately 15,000 people in the United States each year. The novel proteasome inhibitor bortezomib has shown antitumor activity in preclinical studies and has entered clinical trials, with encouraging results to date. METHODS We review and summarize preclinical work demonstrating the tumoricidal effects of pro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia
سال: 2006
ISSN: 0887-6924,1476-5551
DOI: 10.1038/sj.leu.2404278